Peptide‐Heterocycle Conjugates as Antifungals Against Cryptococcosis
- 24 June 2022
- journal article
- research article
- Published by Wiley in Asian Journal of Organic Chemistry
- Vol. 11 (7)
Abstract
In last three decades, only one new USFDA approved antifungal drug (echinocandin) was introduced into the clinics. The identification of new scaffolds with novel mechanisms of action is an important goal of current antifungal research. Herein, we describe the design, synthesis and in vitro antimicrobial activities of heterocycle‐His(2‐aryl)‐Arg‐NHBzl conjugates as a new structural class of peptidomimetics with promising antifungal activity against Cryptococcus neoformans (IC50 values ranging between 2.13–14.57 μg mL−1). The most potent analog, quinolinyl‐His(2‐tert‐butylphenyl)‐Arg‐NHBzl (17 f) exhibited IC50 and MIC values of 2.13 and 2.50 μg mL−1, respectively against C. neoformans.Keywords
This publication has 26 references indexed in Scilit:
- Microwave-assisted solution phase peptide synthesis in neat waterRSC Advances, 2013
- Properties and mechanisms of action of naturally occurring antifungal peptidesCellular and Molecular Life Sciences, 2013
- Rapid microwave-assisted solution-phase peptide synthesisTetrahedron Letters, 2012
- Regiospecific Direct C-H Arylation at the 2-Position of l-Histidine Using Arylboronic AcidsSynlett, 2012
- Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2010
- New Antimicrobial Hexapeptides: Synthesis, Antimicrobial Activities, Cytotoxicity, and Mechanistic StudiesChemMedChem, 2009
- Antimicrobial and host-defense peptides as new anti-infective therapeutic strategiesNature Biotechnology, 2006
- Antibacterial peptides for therapeutic use: obstacles and realistic outlookCurrent Opinion in Pharmacology, 2006
- Cryptococcal meningitisBritish Medical Bulletin, 2004
- Mechanisms of Antimicrobial Peptide Action and ResistancePharmacological Reviews, 2003